Perrigo Cash Flow from Operating Activities 2010-2024 | PRGO
Perrigo cash flow from operating activities from 2010 to 2024. Cash flow from operating activities can be defined as a company's cash flows from operations.
| Perrigo Annual Cash Flow Ops (Millions of US $) |
|
|---|---|
| 2024 | $363 |
| 2023 | $406 |
| 2022 | $307 |
| 2021 | $156 |
| 2020 | $636 |
| 2019 | $388 |
| 2018 | $593 |
| 2017 | $699 |
| 2016 | $655 |
| 2015 | $201 |
| 2015 | $855 |
| 2014 | $633 |
| 2013 | $554 |
| 2012 | $513 |
| 2011 | $374 |
| 2010 | $332 |
| 2009 | $240 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $3.497B | $4.373B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||